GO:0070743 interleukin-23 complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070743 (interleukin-23 complex) is a secreted heterodimeric cytokine complex composed of IL23A (p19) and IL12B (p40) subunits.
• The complex signals through the IL-23 receptor to drive Th17 cell differentiation and maintenance, linking innate and adaptive immunity.
• Dysregulated interleukin-23 complex activity is a central pathogenic driver in psoriasis, psoriatic arthritis, inflammatory bowel disease, and hidradenitis suppurativa.
• IL23A and IL12B are the two essential genes encoding the complex; IL12B is shared with the IL-12 cytokine, creating unique regulatory challenges.
• Therapeutic blockade of the interleukin-23 complex (e.g., anti-p19 or anti-p40 antibodies) is clinically validated in multiple immune-mediated diseases.
• CRISPR knockout, knock-in, and overexpression models of IL23A and IL12B enable causal dissection of interleukin-23 complex biology in human cells and organoids.
Description
The interleukin-23 complex (GO:0070743) is a secreted heterodimeric protein complex that belongs to the IL-12 family of cytokines. It is composed of two disulfide-linked subunits: interleukin-23 alpha (p19), encoded by the IL23A gene, and interleukin-12 beta (p40), encoded by the IL12B gene. This complex is a critical immunological playmaker that bridges innate and adaptive immune responses by promoting the differentiation, expansion, and maintenance of T helper 17 (Th17) cells. Because of its central role in chronic inflammatory diseases, the interleukin-23 complex has become a major therapeutic target and a focal point for gene editing research. For researchers, GO:0070743 provides a precise ontological handle for annotating experiments that interrogate the assembly, secretion, and function of this cytokine complex. Unlike its individual subunits, the interleukin-23 complex represents the functional signaling entity that binds the IL-23 receptor and initiates downstream JAK-STAT signaling. Understanding its composition, regulation, and disease associations is essential for developing targeted immunotherapies and for interpreting CRISPR screens that perturb IL23A or IL12B. This article synthesizes authoritative QuickGO annotation data with verified PubMed literature to deliver a research-grade overview of the interleukin-23 complex. It covers the definition, structure, molecular mechanism, key genes, disease links, and state-of-the-art CRISPR and bioinformatics methods used to study this complex in human disease models.
interleukin-23 complex At A Glance
| GO ID | GO:0070743 |
|---|---|
| GO term | interleukin-23 complex |
| Ontology | cellular_component |
| Synonym | IL12B, IL23A, IL-23 complex, p19, p40 |
| Major function | Secreted heterodimeric cytokine complex that drives Th17 cell differentiation and maintenance |
| Subunit composition | IL23A (p19) and IL12B (p40) subunits |
| Cellular localization | Secreted into the extracellular space |
| Associated receptor | IL-23 receptor (IL23R) complex |
| Shared subunit | IL12B (p40) is shared with the IL-12 cytokine complex |
What Is GO:0070743?
The interleukin-23 complex (GO:0070743) is a protein complex that is composed of an interleukin-23 alpha (p19, product of the IL23A gene) and an interleukin-12 beta (p40, product of the IL12B gene) subunit and is secreted into the extracellular space. In other words, it is a heterodimeric cytokine complex that forms when the IL23A and IL12B gene products associate and are secreted, enabling extracellular signaling through the IL-23 receptor.
Why Is interleukin-23 complex Important in Cell Biology?
The interleukin-23 complex is a master regulator of the Th17 immune axis and a validated therapeutic target in multiple chronic inflammatory diseases. Its dysregulation is directly implicated in the pathogenesis of psoriasis, psoriatic arthritis, inflammatory bowel disease, and hidradenitis suppurativa, making it one of the most clinically actionable cytokine complexes in immunology. For researchers, GO:0070743 provides a precise annotation for experiments that manipulate IL23A and IL12B, enabling causal inference about complex assembly, secretion, and downstream signaling in human disease models.
• Central driver of Th17 cell differentiation and maintenance, linking innate and adaptive immunity.
• Validated therapeutic target in psoriasis, with anti-p19 and anti-p40 biologics approved or in development.
• Implicated in the pathogenesis of psoriatic arthritis through IL-23-driven enthesitis and synovitis.
• Key mediator of intestinal inflammation in inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
• Emerging role in hidradenitis suppurativa, a debilitating follicular occlusion disease.
• Shared IL12B (p40) subunit creates unique regulatory and therapeutic considerations versus IL-12.
• Enables CRISPR-based causal dissection of cytokine complex assembly and secretion.
• Provides a model system for studying heterodimeric cytokine trafficking and extracellular secretion.
• Supports biomarker discovery and patient stratification for anti-IL-23 therapies.
• Facilitates functional genomics screens to identify regulators of IL-23 complex production.
Structure and Composition of interleukin-23 complex
Submit composition and heterodimerization
In simple terms: The interleukin-23 complex is made of two different protein chains that pair up before being released from the cell.
The interleukin-23 complex is a heterodimeric cytokine composed of an interleukin-23 alpha (p19) subunit, encoded by IL23A, and an interleukin-12 beta (p40) subunit, encoded by IL12B. These two subunits associate intracellularly to form the functional complex, which is then secreted into the extracellular space. The p40 subunit is shared with the related IL-12 cytokine, which pairs p40 with p35 (IL12A), creating a structural and regulatory intersection between the IL-12 and IL-23 pathways.
Secretion and extracellular localization
In simple terms: Once assembled, the complex is exported out of the cell so it can act on neighboring immune cells.
The interleukin-23 complex is secreted into the extracellular space, where it acts as a soluble cytokine. Secretion is a regulated process that depends on proper subunit folding and assembly within the producing cell, typically activated myeloid cells such as dendritic cells and macrophages. The extracellular localization of the complex is a defining feature of GO:0070743 and distinguishes it from intracellular cytokine precursors.
Receptor binding and signaling complex
In simple terms: The released complex binds to a specific receptor on target cells, triggering a signaling cascade.
Extracellular interleukin-23 complex binds to the IL-23 receptor (IL23R), a heterodimeric receptor composed of IL23R and IL12RB1 subunits. This binding activates JAK-STAT signaling, particularly STAT3, which drives the transcriptional program for Th17 cell differentiation and maintenance. The receptor-ligand interaction is the molecular basis for the complex's immunological function and its central role in chronic inflammation.
Assembly regulation and quality control
In simple terms: Cells carefully control how much of each subunit is made and how they are paired to avoid unwanted cytokine complexes.
The assembly of the interleukin-23 complex is regulated at multiple levels, including transcriptional control of IL23A and IL12B, post-translational modification, and intracellular quality control. Because IL12B (p40) is shared with IL-12, the relative availability of IL23A (p19) versus IL12A (p35) determines whether p40 is incorporated into the interleukin-23 complex or the IL-12 complex. This competitive assembly creates a regulatory node that can be perturbed by CRISPR editing of either subunit.
Structural features of the p19 and p40 subunits
In simple terms: Each subunit has a distinct shape that allows them to fit together and bind the receptor.
The p19 (IL23A) subunit is a four-helix bundle cytokine that confers specificity for the IL-23 receptor, while the p40 (IL12B) subunit is a structurally related cytokine domain that mediates receptor binding and signaling. The heterodimeric interface between p19 and p40 is stabilized by non-covalent interactions and, in some contexts, disulfide bonds. These structural features are critical for the complex's stability, secretion, and biological activity, and they inform the design of therapeutic antibodies that target the complex.
Key Genes Involved in GO:0070743 interleukin-23 complex
The following genes and proteins are directly involved in the interleukin-23 complex (GO:0070743) and its signaling axis.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL23A | Encodes the p19 subunit of the interleukin-23 complex | Essential for complex assembly and secretion; knockout abolishes IL-23 signaling |
| IL12B | Encodes the p40 subunit shared by IL-23 and IL-12 | Knockout disrupts both IL-23 and IL-12 complexes; key therapeutic target |
| IL23R | Encodes the IL-23 receptor subunit | Mediates signaling of the interleukin-23 complex; target of genetic association studies |
| IL12RB1 | Encodes the shared IL-12/IL-23 receptor beta 1 subunit | Required for IL-23 receptor function and downstream JAK-STAT activation |
| JAK2 | Janus kinase that transduces IL-23 receptor signaling | Phosphorylates STAT3 downstream of the interleukin-23 complex |
| TYK2 | Janus kinase associated with IL-23 receptor signaling | Modulates IL-23-driven Th17 responses; drug target |
| STAT3 | Transcription factor activated by IL-23 receptor signaling | Drives Th17 differentiation and inflammatory gene expression |
| RORC | Transcription factor required for Th17 cell differentiation | Downstream effector of interleukin-23 complex signaling |
| IL17A | Effector cytokine produced by Th17 cells | Readout of interleukin-23 complex activity in inflammation |
| IL17F | Effector cytokine produced by Th17 cells | Readout of interleukin-23 complex activity in inflammation |
| IL22 | Effector cytokine produced by Th17 cells | Mediates epithelial responses downstream of IL-23 |
| NFKB1 | Transcription factor involved in inflammatory cytokine induction | Regulates IL23A and IL12B expression in myeloid cells |
| NFKB2 | Transcription factor involved in inflammatory cytokine induction | Regulates IL23A and IL12B expression in myeloid cells |
| IRF4 | Transcription factor regulating IL-23 production | Modulates interleukin-23 complex expression in dendritic cells |
| BATF | Transcription factor regulating IL-23 production | Modulates interleukin-23 complex expression in dendritic cells |
| CARD9 | Adapter protein in antifungal signaling | Links innate sensing to IL-23 production |
| NOD2 | Pattern recognition receptor | Induces IL-23 complex production in response to microbial stimuli |
| TLR2 | Toll-like receptor | Activates IL-23 complex production in myeloid cells |
How Is interleukin-23 complex Regulated?
The production and activity of the interleukin-23 complex are tightly regulated at transcriptional, post-transcriptional, and post-translational levels. In myeloid cells, pattern recognition receptors such as TLR2 and NOD2, together with CARD9 signaling, induce the expression of both IL23A and IL12B, leading to increased assembly and secretion of the complex. Transcription factors including NF-kB, IRF4, and BATF coordinate the expression of these subunits in response to microbial and inflammatory stimuli. Because IL12B (p40) is shared with IL-12, the relative abundance of IL23A (p19) versus IL12A (p35) determines whether p40 is incorporated into the interleukin-23 complex or the IL-12 complex, creating a competitive regulatory node. Post-translational quality control mechanisms ensure that only properly assembled heterodimers are secreted, preventing the release of unpaired subunits. In the context of disease, dysregulated interleukin-23 complex production amplifies Th17 responses and chronic inflammation, as observed in psoriasis and inflammatory bowel disease.
interleukin-23 complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL23A | Psoriasis, IBD, hidradenitis suppurativa | Keratinocyte or intestinal organoid knockout of IL23A |
| IL12B | Psoriasis, psoriatic arthritis, IBD | Myeloid cell line knockout of IL12B |
| IL23R | IBD, psoriasis susceptibility | T cell knock-in of disease-associated IL23R variants |
| STAT3 | Th17-mediated autoimmunity | STAT3 knockout in T cells to block IL-23 signaling |
| IL17A | Psoriasis, IBD effector cytokine | IL17A reporter knock-in for IL-23 response readout |
Psoriasis and psoriatic arthritis
The interleukin-23 complex is a central driver of psoriasis pathogenesis, where it promotes Th17 cell differentiation and the production of effector cytokines such as IL-17A, IL-17F, and IL-22. These cytokines drive keratinocyte hyperproliferation and skin inflammation, hallmarks of psoriatic plaques. In psoriatic arthritis, IL-23 signaling contributes to enthesitis, synovitis, and bone remodeling, linking skin and joint pathology. Therapeutic blockade of the interleukin-23 complex, either through the p19 subunit or the shared p40 subunit, has demonstrated significant clinical efficacy in both conditions.
Inflammatory bowel disease
In inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, the interleukin-23 complex drives chronic intestinal inflammation through Th17 cell activation and innate lymphoid cell responses. Genetic variants in IL23R and other components of the IL-23 pathway are associated with IBD susceptibility. Anti-IL-23 therapies targeting the p19 subunit have shown efficacy in moderate-to-severe IBD, validating the complex as a therapeutic target. The interleukin-23 complex thus represents a key node linking mucosal immune dysregulation to intestinal tissue damage.
Hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease of the follicular unit, and emerging evidence implicates the interleukin-23 complex in its pathogenesis. IL-23-driven Th17 responses contribute to the inflammatory milieu of HS lesions, and therapeutic targeting of the IL-23 pathway is under investigation. The complex's role in HS highlights its broader relevance beyond classical psoriatic and IBD indications.
Other immune-mediated conditions
The interleukin-23 complex has been implicated in additional immune-mediated conditions, including spondyloarthritis and certain autoimmune disorders, where Th17 responses play a pathogenic role. Because the complex bridges innate and adaptive immunity, its dysregulation can amplify inflammation across multiple tissues. Ongoing research continues to define the full spectrum of diseases driven by interleukin-23 complex activity.
From interleukin-23 complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL23A loss abolish interleukin-23 complex secretion? | IL23A knockout in myeloid cell lines or primary dendritic cells |
| Does a disease-associated IL23R variant alter signaling? | IL23R point mutation knock-in in T cell lines |
| Can we tag the p19 subunit to track secretion? | IL23A tagged knock-in with fluorescent or epitope tag |
| Does IL12B overexpression drive IL-23 complex formation? | IL12B overexpression in myeloid cells |
| Which genes regulate interleukin-23 complex production? | CRISPR library screening in activated myeloid cells |
| Does IL-23 complex drive Th17 differentiation? | Co-culture of IL-23-producing cells with naive T cells |
How to Study the interleukin-23 complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of IL23A or IL12B function | Abolish interleukin-23 complex production |
| CRISPR knock-in | Tagged or variant subunit expression | Track complex assembly and secretion |
| RNA-seq | Transcriptional changes | Identify regulators of IL23A and IL12B |
| Proteomics | Protein abundance and interactions | Detect secreted interleukin-23 complex |
| ELISA | Cytokine concentration | Quantify IL-23 complex in supernatants |
| Flow cytometry | Th17 cell frequency | Measure IL-23-driven differentiation |
| Western blot | STAT3 phosphorylation | Assess IL-23 receptor signaling |
| Immunofluorescence | Subcellular localization | Visualize complex trafficking |
CRISPR knockout and knock-in models
CRISPR-Cas9 genome editing enables precise knockout of IL23A or IL12B to abolish interleukin-23 complex production, as well as knock-in of tags or disease-associated variants to study complex assembly and secretion. These models are essential for causal inference in human cells, complementing mouse studies that may not fully recapitulate human cytokine biology.
Transcriptomic and proteomic profiling
RNA sequencing and proteomics can quantify IL23A and IL12B expression and identify co-regulated genes in response to inflammatory stimuli. Secretome proteomics can detect the secreted interleukin-23 complex and its processed subunits, providing direct evidence of complex formation and release.
Functional immune assays
Th17 differentiation assays, cytokine bead arrays, and STAT3 phosphorylation assays measure the functional impact of the interleukin-23 complex on target cells. These assays are used to validate CRISPR-edited models and to test therapeutic antibodies targeting the complex.
Imaging and trafficking studies
Fluorescence microscopy and live-cell imaging of tagged IL23A and IL12B subunits can visualize intracellular assembly and trafficking of the interleukin-23 complex. These methods reveal how mutations or drugs affect complex secretion and extracellular localization.
How CRISPR Can Be Used to Study GO:0070743 interleukin-23 complex
Knockout
CRISPR knockout of IL23A or IL12B completely abolishes production of the interleukin-23 complex, providing a clean genetic model to study its role in Th17 differentiation and inflammation. Knockout of IL12B also disrupts IL-12, so careful interpretation is required to distinguish IL-23-specific effects. These models are widely used to validate therapeutic targeting of the complex.
Point Mutation
Point mutation knock-in can model disease-associated variants in IL23A, IL12B, or IL23R to assess their impact on complex assembly, secretion, or receptor signaling. For example, variants that alter the p19-p40 interface or receptor binding can be introduced into cell lines to study functional consequences. This approach is valuable for precision medicine and genetic association follow-up.
Knock-in
Knock-in of fluorescent or epitope tags into IL23A or IL12B enables real-time tracking of interleukin-23 complex assembly and secretion in live cells. Tagged knock-in models also facilitate purification of the complex for structural and biochemical studies. These models are compatible with high-content imaging and proteomic workflows.
Overexpression
Overexpression of IL23A and IL12B in myeloid or epithelial cells can drive constitutive interleukin-23 complex production, creating a gain-of-function model for studying downstream inflammation. Overexpression models are useful for screening anti-IL-23 therapeutics and for identifying feedback regulators of the complex. They complement knockout studies by revealing sufficiency, not just necessity, of the complex.
How EDITGENE Supports interleukin-23 complex Research
Researchers studying interleukin-23 complex-related genes often need to determine whether a candidate gene is causally involved in complex assembly, secretion, or downstream signaling. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for interleukin-23 complex research.
Frequently Asked Questions About interleukin-23 complex
What is the interleukin-23 complex?
The interleukin-23 complex (GO:0070743) is a secreted heterodimeric cytokine composed of IL23A (p19) and IL12B (p40) subunits that drives Th17 immune responses.
What genes are involved in the interleukin-23 complex?
The core genes are IL23A, encoding p19, and IL12B, encoding p40; signaling involves IL23R, IL12RB1, JAK2, TYK2, and STAT3.
What diseases are associated with the interleukin-23 complex?
It is implicated in psoriasis, psoriatic arthritis, inflammatory bowel disease, and hidradenitis suppurativa.
How is the interleukin-23 complex assembled?
IL23A and IL12B subunits associate intracellularly and are secreted as a heterodimer into the extracellular space.
What is the difference between IL-23 and IL-12?
Both share the IL12B (p40) subunit, but IL-23 pairs p40 with p19 (IL23A), while IL-12 pairs p40 with p35 (IL12A).
How can CRISPR be used to study the interleukin-23 complex?
CRISPR knockout of IL23A or IL12B abolishes complex production, while knock-in and overexpression models enable tracking and gain-of-function studies.
What cell types produce the interleukin-23 complex?
Activated myeloid cells such as dendritic cells and macrophages are major producers of the interleukin-23 complex.
What signaling pathway does the interleukin-23 complex activate?
It activates JAK-STAT signaling, particularly STAT3, through the IL-23 receptor.
Are there therapies targeting the interleukin-23 complex?
Yes, anti-p19 and anti-p40 antibodies that block the interleukin-23 complex are approved or in development for psoriasis, psoriatic arthritis, and IBD.
What GO term describes the interleukin-23 complex?
The Gene Ontology term is GO:0070743, interleukin-23 complex, under the cellular_component ontology.
Conclusion
The interleukin-23 complex (GO:0070743) is a secreted heterodimeric cytokine that serves as a master regulator of Th17 immunity and a validated therapeutic target in psoriasis, psoriatic arthritis, inflammatory bowel disease, and hidradenitis suppurativa. Its composition of IL23A (p19) and IL12B (p40) subunits, shared with IL-12, creates unique regulatory and therapeutic considerations. CRISPR-based models, including knockout, point mutation, knock-in, and overexpression, are indispensable for dissecting the causal roles of IL23A, IL12B, and pathway genes in human disease. EDITGENE provides comprehensive gene editing and screening services to accelerate research on the interleukin-23 complex and to support the development of next-generation immunotherapies.
References
- 1. Yamanaka K et al.. 2021. Pathophysiology of psoriasis: A review.. J Dermatol 48(6):722-731 PMID: 33886133
- 2. Veale DJ et al.. 2018. The pathogenesis of psoriatic arthritis.. Lancet 391(10136):2273-2284 PMID: 29893226
- 3. Stallmach A et al.. 2023. Treatment Strategies in Inflammatory Bowel Diseases.. Dtsch Arztebl Int 120(45):768-778 PMID: 37408514
- 4. Wang Z et al.. 2021. Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation.. Autophagy 17(2):529-552 PMID: 32019420
- 5. Vignali DA et al.. 2012. IL-12 family cytokines: immunological playmakers.. Nat Immunol 13(8):722-8 PMID: 22814351
- 6. Aebisher D et al.. 2024. Key Interleukins in Inflammatory Bowel Disease-A Review of Recent Studies.. Int J Mol Sci 26(1) PMID: 39795980
- 7. Hu P et al.. 2021. The Role of Helper T Cells in Psoriasis.. Front Immunol 12:788940 PMID: 34975883
- 8. Frew JW. 2025. Unravelling the complex pathogenesis of hidradenitis suppurativa.. Br J Dermatol 192(Suppl 1):i3-i14 PMID: 39895594
